Ranbaxy Laboratories Ltd has started exporting anti-cholesterol Atorvastatin Calcium Oral tablets to the US, from its Mohali SEZ facility.
The first consignment of Atorvastatin tablets has been dispatched to the US in March. The supply of Atrovastatin tablets from India supplements the company’s current production from Ohm Laboratories Inc, US.
This assumes significance in the light of the ban imposed by the US Food and Drug Administration in 2008. The US FDA had barred Ranbaxy from importing 30 drugs manufactured at plants in India after it found that the company was not following specified manufacturing practices.
Mr Arun Sawhney, CEO & Managing Director, Ranbaxy, said, “The resumption of supplies from India into the US market, is a significant milestone for Ranbaxy. Going forward, our Mohali facility will cater to the US and other geographies, improving access to medicines, in these regions.”
Ranbaxy’s dosage forms facility at Mohali was approved by the US Food and Drug Administration in October 2011. Thereafter, in the first quarter of 2012, the company received approval from the US FDA to manufacture and market Atorvastatin 10mg, 20mg, 40mg and 80mg tablets.
The new facility at Mohali will manufacture oral solid products for export to US, EU and other countries based on filings and after receiving the necessary approvals.
At 12.40 p.m., the Ranbaxy stock was down 1.97 per cent at Rs 459.75 on the BSE.